Nakamura Y, Yamazaki N, Namikawa K, Uchi H, et al. Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1). BMC Cancer 2026 Mar 4. doi: 10.1186/s12885-026-15829.
PMID: 41781908